Comments 1 - 9 of 9 Search these comments
Dr. Brian Ardis warns America approaching ONE MILLION DEATHS from remdesivir and ventilator homicide
The physician said the protocol he developed last year consisted of regimen of FDA-approved drugs including methylprednisolone, ascorbic acid, and anticoagulant heparin, and has expanded over time “based on the best evolving science” to include anti-androgen therapy, vitamin C, ivermectin, and fluvoxamine.
Though he was never permitted to use ivermectin in his hospital, Marik said he was allowed to use the other medications and enjoyed success with them.
“We did really well compared to national averages,” he said, adding that a Houston-based colleague who was following the protocol told him he saw a hospital mortality rate of less than 10% in COVID patients treated with the multi-drug sequence.
“And then, inexplicably, October the 5th, my hospital system, Sentara Health Care System, sent out a system-wide memorandum basically targeting me personally and banning the use of ivermectin, fluvoxamine, anti-androgen therapy, and discouraging the use of vitamin C,” Marik said.
Instead, Marik said he was pushed to use Remdesivir, a drug which he said “increases your risk of renal failure and liver failure.”
Marik said he “was being forced to use that toxic medication” rather than “the medications I knew that were safe, effective, and cheap,” adding that the week after the memorandum took effect he dealt with seven COVID patients suffering from “COVID pneumonia” and was not permitted to use the drugs he would otherwise have prescribed.
“All seven patients died,” he said. “It was an absolute outrage, including a 32 year old woman and a 40 year old man, and I had to stand by and watch idly as these patients died. It broke my heart and I was broken, so I really had no option. It was either to quit or [file] an injunction against the hospital.”
By November 2020, the WHO declared DO NOT use Remdesivir, as it caused kidney and liver damage and death, yet NIH etc. recommended it; October 4th 2020, Great Barrington said ONLY protect elderly
Nothing else, allow rest of low-risk healthy population live freely, no lockdowns, no school closures, no mask mandates etc.; but Fauci & Birx & Francis Collins refused to listen, killing thousands
Dr. Paul Alexander
18 min ago
No amnesty, none, we drag these people into proper legal inquiries, tribunals and we investigate them and punish them if shown wrong. Punish harshly, take their money and jail as many if it is warranted and declared by judge and jury, tribunals etc.
The Vigilant Fox
@VigilantFox
The FDA Approved Remdesivir Based on a Trial in Which 3 out of 53 Children Died
The trial was conducted by Gilead, the developer of remdesivir. There was no control group.
Mortality rate of children against COVID - < 0.005%.
Mortality rate of children with remdesivir - 5.66%.
The open-label DisCoVeRy trial enrolled Covid-19 patients across 48 sites in Europe to test a handful of treatments, including remdesivir, lopinavir–ritonavir, lopinavir–ritonavir and interferon beta-1a, and hydroxychloroquine. To participate, patients had to show symptoms for seven days and require oxygen support. A total of 429 patients were randomized to receive remdesivir plus standard of care, while 428 were assigned to standard of care alone.
Researchers measured remdesivir’s efficacy on day 15, using the World Health Organization’s seven-point scale — only to find that no clinical benefit was observed in patients who received the drug over those who got standard of care alone. And while previous studies have linked remdesivir to a faster time to recovery, that result was not seen in the DisCoVeRy trial.
Here’s how patients were distributed on the WHO’s scale:
Not hospitalised, no limitations on activities (61 [15%] of 414 in the remdesivir group vs 73 [17%] of 418 in the control group); (2) not hospitalised, limitation on activities (129 [31%] vs 132 [32%]); (3) hospitalised, not requiring supplemental oxygen (50 [12%] vs 29 [7%]); (4) hospitalised, requiring supplemental oxygen (76 [18%] vs 67 [16%]); (5) hospitalised, on non-invasive ventilation or high flow oxygen devices (15 [4%] vs 14 [3%]); (6) hospitalised, on invasive mechanical ventilation or extracorporeal membrane oxygenation (62 [15%] vs 79 [19%]); (7) death (21 [5%] vs 24 [6%]).
The results bring into question Veklury’s approval — and also its hefty $3,000-plus price tag.
The FDA granted remdesivir full approval back in October based on three randomized control studies, including the full data from the NIAID-sponsored Phase III ACTT-1 trial published on Oct. 8, according to Gilead. That study showed a reduction in recovery time by five days in hospitalized Covid-19 patients and by seven days in patients requiring oxygen.
Gilead had previously been granted a partial EUA in early May to treat severe Covid-19, which was later expanded in August to include all hospitalized adults and children after a Gilead-led study showed modest efficacy.
But the week before remdesivir was approved, the WHO released a study showing the antiviral had no substantial effect on improving mortality rates, reducing the amount of patients needing ventilators or shortening hospital stays. In this trial, remdesivir had no material effects on ventilation initiation or time to discharge.
In an FAQ, the FDA had said that since Gilead’s ACTT-1 study was randomized, double-blinded and placebo-controlled (whereas the WHO trial was open-label), they found ACTT-1 to be “better suited” in a time to recovery endpoint.
In April, Gilead CEO Dan O’Day said about half of all hospitalized patients with Covid-19 in the US are treated with Veklury.
https://endpts.com/european-study-finds-that-gileads-covid-19-antiviral-remdesivir-shows-no-clinical-benefit/